• 1
    Bas M, Hoffmann TK, Kojda G. Evaluation and management of angioedema of the head and neck. Curr Opin Otolaryngol Head Neck Surg 2006;14:170175.
  • 2
    Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf 2001;24:599606.
  • 3
    Zuberbier T. Urticaria. Allergy 2003;58: 12241234.
  • 4
    Morwood K, Gillis D, Smith W, Kette F. Aspirin-sensitive asthma. Intern Med J 2005;35:240246.
  • 5
    Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol 2005;53: 373388.
  • 6
    Alsenz J, Bork K, Loos M. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med 1987;316: 13601366.
  • 7
    Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992;71:206215.
  • 8
    Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000;356:608609.
  • 9
    Agostoni A, Ygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004;114:S51S131.
  • 10
    Gainer JV, Nadeau JH, Ryder D, Brown NJ. Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol 1996;98: 283287.
  • 11
    McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006;332: 11771181.
  • 12
    Malde B, Regalado J, Greenberger PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol 2007;98:5763.
  • 13
    Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893190.
  • 14
    Abelous J, Bardier E. Les substance hypotensive de lúrine humaine normale. CR Soc Biol 1909;66:511512.
  • 15
    Sharma JN. Does kinin mediate the hypotensive action of angiotensin converting enzyme (ACE) inhibitors? Gen Pharmacol 1990;21:451457.
  • 16
    Clements J, Hooper J, Dong Y, Harvey T. The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions. Biol Chem 2001; 382:514.
  • 17
    Britos J, Nolly H. Kinin-forming enzyme of rat cardiac tissue. Subcellular distribution and biochemical properties. Hypertension 1981;3:II-5.
  • 18
    Sharma JN, Kesavarao U. Cardiac kallikrein in hypertensive and normotensive rats with and without diabetes. Immunopharmacology 1996;33: 341343.
  • 19
    Sharma JN, Uma K, Yusof AP. Left ventricular hypertrophy and its relation to the cardiac kinin-forming system in hypertensive and diabetic rats. Int J Cardiol 1998;63:229235.
  • 20
    Nustad K, Vaaje K, Pierce JV. Synthesis of kallikreins by rat kidney slices. Br J Pharmacol 1975;53:229234.
  • 21
    Yang HY, Erdos EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 1970;214:374376.
  • 22
    Yang HY, Erdos EG, Levin Y. Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). J Pharmacol Exp Ther 1971;177:291300.
  • 23
    Vavrek RJ, Stewart JM. Competitive antagonists of bradykinin. Peptides 1985;6:161164.
  • 24
    Roberts RA. Bradykinin receptors: characterization, distribution and mechanisms of signal transduction. Prog Growth Factor Res 1989;1: 237252.
  • 25
    Regoli D, Rhaleb NE, Drapeau G, Dion S. Kinin receptor subtypes. J Cardiovasc Pharmacol 1990;15(Suppl. 6):S30S38.
  • 26
    Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980;32:146.
  • 27
    Hess JF, Borkowski JA, Young GS, Strader CD, Ransom RW. Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Biophys Res Commun 1992;184:260268.
  • 28
    McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P et al. Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci U S A 1991;88:77247728.
  • 29
    Menke JG, Borkowski JA, Bierilo KK, MacNeil T, Derrick AW, Schneck KA et al. Expression cloning of a human B1 bradykinin receptor. J Biol Chem 1994;269:2158321586.
  • 30
    Ma JX, Wang DZ, Ward DC, Chen L, Dessai T, Chao J et al. Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. Genomics 1994;23:362369.
  • 31
    Chai KX, Ni A, Wang D, Ward DC, Chao J, Chao L. Genomic DNA sequence, expression, and chromosomal localization of the human B1 bradykinin receptor gene BDKRB1. Genomics 1996;31:5157.
  • 32
    Regoli DC, Marceau F, Lavigne J. Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol 1981;71:105115.
  • 33
    Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44:180.
  • 34
    Busse R, Fleming I. Regulation of endothelium-derived vasoactive autacoid production by hemodynamic forces. Trends Pharmacol Sci 2003;24: 2429.
  • 35
    Venema VJ, Ju H, Sun J, Eaton DC, Marrero MB, Venema RC. Bradykinin stimulates the tyrosine phosphorylation and bradykinin B2 receptor association of phospholipase C gamma 1 in vascular endothelial cells. Biochem Biophys Res Commun 1998;246:7075.
  • 36
    Fleming I, Busse R. Tyrosine phosphorylation and bradykinin-induced signaling in endothelial cells. Am J Cardiol 1997;80:102A109A.
  • 37
    Adams DJ, Barakeh J, Laskey R, Van BC. Ion channels and regulation of intracellular calcium in vascular endothelial cells. FASEB J 1989;3: 23892400.
  • 38
    Martin TW, Wysolmerski RB. Ca2+-dependent and Ca2+-independent pathways for release of arachidonic acid from phosphatidylinositol in endothelial cells. J Biol Chem 1987;262:1308613092.
  • 39
    Ju H, Venema VJ, Liang H, Harris MB, Zou R, Venema RC. Bradykinin activates the Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) pathway in vascular endothelial cells: localization of JAK/STAT signalling proteins in plasmalemmal caveolae. Biochem J 2000;351:257264.
  • 40
    Bae SW, Kim HS, Cha YN, Park YS, Jo SA, Jo I. Rapid increase in endothelial nitric oxide production by bradykinin is mediated by protein kinase A signaling pathway. Biochem Biophys Res Commun 2003;306:981987.
  • 41
    Madeddu P, Emanueli C, Gaspa L, Salis B, Milia AF, Chao L et al. Role of the bradykinin B2 receptor in the maturation of blood pressure phenotype: lesson from transgenic and knockout mice. Immunopharmacology 1999;44:913.
  • 42
    Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE III. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002;109:10571063.
  • 43
    Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation 1995;92:34243430.
  • 44
    Hall JM. Bradykinin receptors: pharmacological properties and biological roles. Pharmacol Ther 1992;56: 131190.
  • 45
    Ellis EF, Heizer ML, Hambrecht GS, Holt SA, Stewart JM, Vavrek RJ. Inhibition of bradykinin- and kallikrein-induced cerebral arteriolar dilation by a specific bradykinin antagonist. Stroke 1987;18:792795.
  • 46
    Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004;3: 845852.
  • 47
    Duchene J, Schanstra JP, Pecher C, Pizard A, Susini C, Esteve JP et al. A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation. J Biol Chem 2002;277:4037540383.
  • 48
    Hong SL. Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. Thromb Res 1980;18:787795.
  • 49
    Cocks TM, Angus JA, Campbell JH, Campbell GR. Release and properties of endothelium-derived relaxing factor (EDRF) from endothelial cells in culture. J Cell Physiol 1985;123:310320.
  • 50
    Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524526.
  • 51
    Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454456.
  • 52
    Mombouli JV, Nakashima M, Hamra M, Vanhoutte PM. Endothelium-dependent relaxation and hyperpolarization evoked by bradykinin in canine coronary arteries: enhancement by exercise-training. Br J Pharmacol 1996;117:413418.
  • 53
    Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985;66:835839.
  • 54
    Giannella E, Mochmann HC, Levi R. Ischemic preconditioning prevents the impairment of hypoxic coronary vasodilatation caused by ischemia/reperfusion: role of adenosine A1/A3 and bradykinin B2 receptor activation. Circ Res 1997;81:415422.
  • 55
    Zhu P, Zaugg CE, Simper D, Hornstein P, Allegrini PR, Buser PT. Bradykinin improves postischaemic recovery in the rat heart: role of high energy phosphates, nitric oxide, and prostacyclin. Cardiovasc Res 1995;29:658663.
  • 56
    Leesar MA, Stoddard MF, Manchikalapudi S, Bolli R. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J Am Coll Cardiol 1999;34:639650.
  • 57
    Ritchie RH, Marsh JD, Lancaster WD, Diglio CA, Schiebinger RJ. Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells. Hypertension 1998;31:3944.
  • 58
    Maestri R, Milia AF, Salis MB, Graiani G, Lagrasta C, Monica M et al. Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension 2003;41:11511155.
  • 59
    Fuller RW, Dixon CM, Cuss FM, Barnes PJ. Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis 1987; 135:176180.
  • 60
    Tsukagoshi H, Sun J, Kwon O, Barnes PJ, Chung KF. Role of neutral endopeptidase in bronchial hyperresponsiveness to bradykinin induced by IL-1 beta. J Appl Physiol 1995;78: 921927.
  • 61
    Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension 2000;36:127131.
  • 62
    Hulsmann AR, Raatgeep HR, Saxena PR, Kerrebijn KF, De Jongste JC. Bradykinin-induced contraction of human peripheral airways mediated by both bradykinin beta 2 and thromboxane prostanoid receptors. Am J Respir Crit Care Med 1994;150:10121018.
  • 63
    Alfie ME, Yang XP, Hess F, Carretero OA. Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 1996;224:625630.
  • 64
    Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis MP, Glorioso N et al. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 1997;96:35703578.
  • 65
    Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev 1998;50:357386.
  • 66
    Feletou M, Bonnardel E, Canet E. Bradykinin and changes in microvascular permeability in the hamster cheek pouch: role of nitric oxide. Br J Pharmacol 1996;118:13711376.
  • 67
    Campos MM, Souza GE, Calixto JB. In vivo B1 kinin-receptor upregulation. Evidence for involvement of protein kinases and nuclear factor kappaB pathways. Br J Pharmacol 1999; 127:18511859.
  • 68
    Dray A. Kinins and their receptors in hyperalgesia. Can J Physiol Pharmacol 1997;75:704712.
  • 69
    Lerner UH. Regulation of bone metabolism by the kallikrein-kinin system, the coagulation cascade, and the acute-phase reactants. Oral Surg Oral Med Oral Pathol 1994;78:481493.
  • 70
    Cruwys SC, Garrett NE, Perkins MN, Blake DR, Kidd BL. The role of bradykinin B1 receptors in the maintenance of intra-articular plasma extravasation in chronic antigen-induced arthritis. Br J Pharmacol 1994;113:940944.
  • 71
    Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. Eur J Pharmacol 2001;429:161176.
  • 72
    Wang C, Chao L, Chao J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 1995;95:17101716.
  • 73
    Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA Jr, Walther T et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A 2000;97:81408145.
  • 74
    Ni A, Yin H, Agata J, Yang Z, Chao L, Chao J. Overexpression of kinin B1 receptors induces hypertensive response to des-Arg9-bradykinin and susceptibility to inflammation. J Biol Chem 2003;278:219225.
  • 75
    Yang C, Hsu WH. Glucose-dependency of bradykinin-induced insulin secretion from the perfused rat pancreas. Regul Pept 1997;71:2328.
  • 76
    Damas J, Bourdon V, Lefebvre PJ. Insulin sensitivity, clearance and release in kininogen-deficient rats. Exp Physiol 1999;84:549557.
  • 77
    Duka I, Shenouda S, Johns C, Kintsurashvili E, Gavras I, Gavras H. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension 2001;38:13551360.
  • 78
    Rett K, Wicklmayr M, Dietze GJ. Metabolic effects of kinins: historical and recent developments. J Cardiovasc Pharmacol 1990;15(Suppl. 6):S57S59.
  • 79
    Kishi K, Muromoto N, Nakaya Y, Miyata I, Hagi A, Hayashi H et al. Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. Diabetes 1998;47: 550558.
  • 80
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145153.
  • 81
    Goring HD, Bork K, Spath PJ, Bauer R, Ziemer A, Hintner H et al. Hereditary angioedema in the German-speaking region. Hautarzt 1998;49: 114122.
  • 82
    Cicardi M, Zingale L, Zanichelli A, Pappalardo E, Cicardi B. C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol 2005; 27:286298.
  • 83
    Joseph K, Kaplan AP. Formation of bradykinin: a major contributor to the innate inflammatory response. Adv Immunol 2005;86:159208.
  • 84
    Bowen T, Cicardi M, Farkas H, Bork K, Kreuz W, Zingale L et al. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol 2004; 114:629637.
  • 85
    Blanch A, Roche O, Urrutia I, Gamboa P, Fontan G, Lopez-Trascasa M. First case of homozygous C1 inhibitor deficiency. J Allergy Clin Immunol 2006;118:13301335.
  • 86
    Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003;82:274281.
  • 87
    Markovic SN, Inwards DJ, Frigas EA, Phyliky RP. Acquired C1 esterase inhibitor deficiency. Ann Intern Med 2000;132:144150.
  • 88
    Danielsson A, Nilsson TK, Uddenfeldt P. Alterations in C1 inhibitor and clotting factor concentrations in primary biliary cirrhosis and other chronic liver diseases. Scand J Gastro- enterol 1990;25:149154.
  • 89
    Cohen H, Hunt JB, Dixit M, Kanwar S, Thomas HC. Decreased contact factor mediated fibrinolysis in cirrhosis. Br J Haematol 1993;85:542545.
  • 90
    Gaur S, Cooley J, Aish L, Weinstein R. Lymphoma-associated paraneoplastic angioedema with normal C1-inhibitor activity: does danazol work? Am J Hematol 2004;77:296298.
  • 91
    Monnier N, Ponard D, Duponchel C, Csopaki F, Bouillet L, Tosi M et al. Characterisation of a new C1 inhibitor mutant in a patient with hepatocellular carcinoma. Mol Immunol 2006;43:21612168.
  • 92
    Lefebvre J, Murphey LJ, Hartert TV, Jiao SR, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 2002;39: 460464.
  • 93
    Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129:169S173S.
  • 94
    Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:12851292.
  • 95
    Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998;351:16931697.
  • 96
    Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103111.
  • 97
    Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005;111:315320.
  • 98
    Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334: 16491654.
  • 99
    Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998;31:349355.
  • 100
    Hellebrand MC, Kojda G, Hoffmann TK, Bas M. Angioedema due to ACE inhibitors and AT(1) receptor antagonists. Hautarzt 2005;57:808810.
  • 101
    Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:20072018.
  • 102
    Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:20262033.
  • 103
    Kaplan NM, Opie LH. Controversies in hypertension. Lancet 2006;367: 168176.
  • 104
    Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med 2003;114:294298.
  • 105
    Bouillet L, Ponard D, Drouet C, Jullien D, Massot C. Angioedema and oral contraception. Dermatology 2003;206:106109.
  • 106
    Pichler WJ, Lehner R, Spath PJ. Recurrent angioedema associated with hypogonadism or anti-androgen therapy. Ann Allergy 1989;63:301305.
  • 107
    Visy B, Fust G, Varga L, Szendei G, Takacs E, Karadi I et al. Sex hormones in hereditary angioneurotic oedema. Clin Endocrinol (Oxf) 2004;60: 508515.
  • 108
    Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffre D, Nussberger J. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 1999;44:2125.
  • 109
    Berkun Y, Shalit M. Hereditary angioedema first apparent in the ninth decade during treatment with ACE inhibitor. Ann Allergy Asthma Immunol 2001;87:138139.
  • 110
    Bas M, Kojda G, Bier H, Hoffmann TK. Durch ACE-Hemmer induziertes Angioödem des Kopf-Hals-Bereichs. Eine Frage der Zeit? HNO 2004;52: 886890.
  • 111
    Bas M, Hoffmann TK, Bier H, Kojda G. Increased C-reactive protein in ACE-inhibitor-induced angioedema. Br J Clin Pharmacol 2005;59:233238.
  • 112
    Davis AE III. The pathophysiology of hereditary angioedema. Clin Immunol 2005;114:39.
  • 113
    Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005;139:379394.
  • 114
    Shiber JR. Angioedema of the arytenoids. N Engl J Med 2005;353:e15.
  • 115
    Kojda G, Hafner D, Behne M, Wilhelm M. Pharmakologie Toxikologie Systematisch, 2nd edn. Bremen, London, Boston: UNI-MED AG, 2002.
  • 116
    Farkas H, Harmat G, Fust G, Varga L, Visy B. Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol 2002;13: 153161.
  • 117
    Taparia M, Cordingley FT, Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol 2002;68:307309.
  • 118
    Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999;57:10051032.
  • 119
    Bucca C. Take the side-effects of drugs into account. Lancet 2004;364:1285.
  • 120
    Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf 2002; 25:7376.
  • 121
    Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976;295:14441448.
  • 122
    Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999;353:10661067.
  • 123
    Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004;164:910913.
  • 124
    Bas M, Kojda G. Angioödem nach Einnahme von Irbesartan [Angioedema induced by irbesartan]. Apothekenmagazin 2005;23:254255.
  • 125
    Van Doorn MB, Burggraaf J, Van Dam T, Eerenberg A, Levi M, Hack CE et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005;116:876883.
  • 126
    Levy JH, O’Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 2006; 15:10771090.
  • 127
    Caballero T, Lopez-Serrano C. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J Allergy Clin Immunol 2006; 117:476477.
  • 128
    Icatibant. HOE 140, JE 049, JE049. Drugs R D 2005;6:239244.
  • 129
    Proud D, Bathon JM, Togias AG, Naclerio RM. Inhibition of the response to nasal provocation with bradykinin by HOE-140: efficacy and duration of action. Can J Physiol Pharmacol 1995;73:820826.
  • 130
    Rosenkranz B, Bork K, Frank J. Proof-of-concept study of icatibant (JE 049), a bradykinin B2 receptor antagonist in treatment of hereditary angioedema. Clin Pharmacol Ther 2005; 77:2 (Abstract).
  • 131
    Bas M, Bier H, Greve J, Kojda G, Hoffmann TK. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B-2-receptor antagonist icatibant. Allergy 2006;61:14901492.